Abstract 4691
Background
Acute promyelocytic leukemia (APL) is strongly related to obesity. APL patients have significantly higher body mass index (BMI) than other acute leukemia. In APL patients, BMI over 30 kg/m2 is reported to be a risk factor of all trans retinoic acid (ATRA) induced differentiation syndrome (DS), and associated with inferior disease free survival (DFS) and overall survival (OS). We assessed the impact of obesity associated various factors on APL clinical course.
Methods
We retrospectively reviewed clinical records of the APL patients in our center since January 2008 to May 2019. We used Fisher’s exact test in univariate analysis, logistic regression in multivariate analysis, logrank test in survival analysis.
Results
51 patients were included in this study. The median age was 57 (range: 19-88), 24 females and 27 males. The median BMI was 23.1, 8 (15%) had BMI over 30 kg/m2. All patients were administered ATRA only or ATRA plus anthracycline based chemotherapy. 35 (68%) developed DIC at diagnosis, 18 (35%) developed DS by ATRA administration.47 (92%) achieved complete remission, median suvival was 1304 days (1-6608).9 (17%) experienced relapse.8 (15%) were died by bleeding, another cancer, organ failure. BMI over 30 kg/m2 was associated with high visceral and subcutaneous fat volume(P = 0.01, respectively). High triglyceride (TG) and LDL-cholesterol were independent of high BMI (P = 0.67, =0.54, respectively). In univariate and multivariate analysis, only high TG (over 150 mg/dl) was significantly associated with DIC (odds ratio (OR)= 10.6 (1.6-126.0), p = 0.004, OR = 11.6 (1.9-67.5), p = 0.006, respectively) and DS (OR = 7.31 (1.1-84.2), p = 0.02, OR = 7.7 (1.3-44.0), p = 0.02). BMI, TG, LDL, visceral or subcutaneous fat volume were not significantly affect with OS and DFS. DS onset or high white blood cell count were associated with inferior OS (P = 0.03) or PFS (P = 0.01).
Conclusions
High TG was a major risk factor of DIC and DS in APL treatment. It is possible that TG metabolic pathway will be linked to DIC and DS pathogenesis. Low fat diet or hyperlipidemia treatment may decrease DIC and DS progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract
5638 - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.
Presenter: Laura Gutiérrez Sainz
Session: Poster Display session 1
Resources:
Abstract
5182 - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.
Presenter: Alaa Abufara
Session: Poster Display session 1
Resources:
Abstract
1504 - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients
Presenter: Jennifer Le-rademacher
Session: Poster Display session 1
Resources:
Abstract
3972 - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).
Presenter: Salvatore Paiella
Session: Poster Display session 1
Resources:
Abstract
2313 - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)
Presenter: M Julia Lostes Bardaji
Session: Poster Display session 1
Resources:
Abstract
5219 - Clinical & nutritional determinants of quality of life in patients with incurable cancer
Presenter: Louise Daly
Session: Poster Display session 1
Resources:
Abstract
4075 - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Presenter: In Gyu Hwang
Session: Poster Display session 1
Resources:
Abstract
4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).
Presenter: Ilaria Trestini
Session: Poster Display session 1
Resources:
Abstract
1210 - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy
Presenter: Emilien Billon
Session: Poster Display session 1
Resources:
Abstract